Hypersensitivity Pneumonitis clinical trials at UCSF

1 research study open to eligible people

Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
open to eligible people ages 18 years and up
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
San Francisco, California and other locations

Last updated: April 1, 2026